NDAORALTABLETPriority Review
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOXIN (dextrothyroxine sodium) is an oral tablet containing the dextro-isomer of thyroxine, used as a lipid-lowering agent to treat hypercholesterolemia. The mechanism involves thyroid hormone activity to reduce serum cholesterol levels. This is a legacy product approved in 1967 with limited modern clinical use.
LOE Approaching
This legacy product is approaching loss of exclusivity with minimal commercial infrastructure, indicating limited career growth opportunities and potential team contraction.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLOXIN presents minimal career development potential due to its LOE-approaching status and zero linked job openings. Employment on this legacy product typically involves defensive maintenance rather than strategic growth initiatives. Professionals should view CHOLOXIN roles as short-term or transition positions within a larger portfolio context.
Brand ManagerField Sales Representative
Worked on CHOLOXIN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.